Navigation Links
Different subtypes of triple-negative breast cancer respond to different therapies
Date:6/27/2011

Vanderbilt-Ingram Cancer Center researchers have identified six subtypes of an aggressive and difficult-to-treat form of breast cancer, called "triple-negative breast cancer (TNBC)."

In the July issue of the Journal of Clinical Investigation, Cancer Center Director Jennifer Pietenpol, Ph.D., and colleagues describe the molecular features of these six distinct subtypes and identify chemotherapies to which the different subtypes respond in cultured cells and animal tumor models. Knowing the specific subtype could help physicians determine which therapies would work best in patients with TNBC and also inform the discovery and development of new drugs to treat this aggressive form of breast cancer, the authors suggest.

Triple negative breast cancers (TNBC) account for 10 percent to 20 percent of all breast cancers and tend to be more aggressive than other types of breast cancer.

"It's a pretty significant health problem from the standpoint that 11 percent of Caucasians, 17 percent of Hispanics, and 25 percent of African-Americans have this type of breast cancer," Pietenpol said.

While some patients with TNBC initially respond well to standard chemotherapy, these tumors are more likely to recur after treatment and have a poorer prognosis (less than 30 percent of women with metastatic TNBC which has spread outside the breast survive 5 years).

The difficulty in treating these tumors stems from what they lack.

The term "triple-negative breast cancer," explained Pietenpol, "is just a definition of what (the cancer) isn't."

TNBC tumors lack the estrogen receptors (ER) and progesterone receptors (PR) that drive the majority (about 60 percent) of breast cancers. They also show no amplification of another receptor, called HER2, which drives about 20 percent to 30 percent of breast cancers.

The absence of these receptors means that the tumors are unlikely to respond to hormone therapies like tamoxifen and to therapies ta
'/>"/>

Contact: Dagny Stuart
dagny.stuart@Vanderbilt.Edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Reading Arabic or English May Tax Brain Differently
2. Study finds much different work histories for disability rejects, beneficiaries
3. Breast Cancer Recurrence Rates Appear Different When Radiation Used
4. Vitamin D deficiency is associated with different types of obesity in black and white children
5. Signaling pathway reveals mechanism for B cell differentiation in immune response
6. Men and Women May Truly See Things Differently
7. Two Different Heart Drugs May Work Equally Well for High-Risk Patients
8. Many Moms Have Kids With Different Dads, U.S. Study Finds
9. Different genes influence smoking risk during adolescence and adulthood
10. Surviving Melanoma May Take Different Toll on Women, Men
11. Women with eating disorders draw a different picture of themselves than women without
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... Based ... GROUP is internationally known as an industry leader specializing in surplus used medical ... selling more than 100,000 pieces of medical equipment every year. Erik Tivin, Chairman ...
(Date:9/2/2015)... ... 2015 , ... “ G-Hold ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... a tablet while reducing the likelihood of it dropping. , Tablets like the iPad ...
(Date:9/2/2015)... NC (PRWEB) , ... September 02, 2015 , ... ... IT and business services, has been named to the Inc. 5000 List, an ... has been publishing this list for 34 years, and this achievement puts Canopy ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... reputation for the telling the truth about medicine and health, truths that other ... video blog, where he plans to regularly debunk certain misconceptions surrounding cholesterol, metabolically ...
(Date:9/1/2015)... Miami, FL (PRWEB) , ... September 01, 2015 ... ... Food and Drug Administration (FDA) for the treatment of androgenic alopecia in adults, ... the brand new laser therapy cap, while also demonstrating its safety when used ...
Breaking Medicine News(10 mins):Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Canopy Partners Named to 2015 Inc. 5000 Fastest Growing Companies List 2Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Capillus82™ Laser Therapy Cap Receives FDA Clearance for Treatment of Hair Loss 2
... from around the world met at a conference in ... in obesity. One line of discussion looked at factors ... it might be avoided. , Co-chairs of the conference, ... Research and Dr Jennifer Lovejoy from the University of ...
... directed KH Real Estate to issue a boil water advisory to ... Armstrong County, after samples taken by DEP tested positive for fecal ... received complaints from residents after two customers were hospitalized with intestinal ... for the bacteria. , , ...
... NEW YORK, Nov. 24, 2008 Forest Laboratories, Inc. (NYSE: ... and Trademark Office ("USPTO") has closed prosecution on the merits ... confirmed the validity of all of the previously granted claims. ... Intent to Issue Ex Parte Reexamination Certificate for U.S. Patent ...
... treatment system for advanced radiation therapy, today announced that Rafael (Ralph) ... effective December 1, 2008. Mr. Vaello, who will report to TomoTherapy ... the sales and field marketing group for Philips Healthcare’s Oncology Imaging ... ...
... celebrity trainer Ramona Braganza offers tips to stay trim over the holidays and ... without packing on the pounds. , , ... trimmings: , , , ... before you load your plate for dinner or head out to a holiday ...
... of them currently abstain from alcohol, drugs , , MONDAY, ... Americans over the age of 12 participate in self-help ... 2.3 million who currently abstain from use of these ... Monday by the federal Substance Abuse and Mental Health ...
Cached Medicine News:Health News:Why women should eat less, move more and consider wearing transdermal HRT patches during menopause 2Health News:Pennsylvania DEP Directs Shadyside Water Supply to Issue Boil Water Advisory 2Health News:USPTO Confirms Validity of Bystolic(R) Patent 2Health News: TomoTherapy Names Rafael Vaello Vice President of Global Sales : Former Philips Healthcare executive brings proven sales experience in oncology, imaging industries 2Health News:Tip Sheet: Celebrity Trainer, Ramona Braganza's Tips To Keep Off Those Extra Holiday Pounds 2Health News:5 Million People a Year Use Self-Help Addiction Programs 2
(Date:9/1/2015)... SAN DIEGO and BEDFORD, Mass. ... firm Robbins Arroyo LLP is investigating whether ... violated the Securities and Exchange Act of 1934.  ConforMIS ... Image-to-Implant technology platform to develop, manufacture, and sell joint ... fit each patient,s unique anatomy. View this ...
(Date:9/1/2015)... and Delaware , United ... (ASX: IVX; "Company" or "Invion"), is pleased to announce that ... securities to an institutional investor in the United ... proceeds of approximately A$1.001 million ("Placement") by the issue of ... of $0.014 per share. The Company has ...
(Date:9/1/2015)... and OR YEHUDA, Israel , Sept. ... HTWR ), a leading innovator of less invasive, ... of advanced heart failure, announced today that it has ... Cardio, Ltd . ("Valtech").  Valtech is a privately held ... and transcatheter valve repair and replacement devices for the ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 2HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 3HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 4HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 5HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 6HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 7HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 8HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 9HeartWare International Enters Into Definitive Agreement To Acquire Valtech Cardio, Ltd. 10
... March 23 MicroMass Communications, Inc., a world leader in behavioral marketing, has been named agency of record ... new center and its mission of promoting the growth of North Carolina ,s advanced medical technologies industry. , ... ... , ...
... , March 23 Portola Pharmaceuticals, Inc. ... human Phase 1 trial in healthy volunteers of PRT062607, ... treat chronic inflammatory diseases, including rheumatoid arthritis (RA), and ... In preclinical in vivo models of RA, ...
Cached Medicine Technology:MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 2MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 3MicroMass Named Agency of Record for North Carolina Advanced Medical Technologies Center of Innovation 4Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications 2Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications 3Portola Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of PRT062607, an Oral, Syk-Specific Inhibitor for Chronic Inflammatory Disease Indications 4
... standard, corrected curve trial lenses are ground with ... Marco refractors and are invaluable in treating low ... other manufacturers contain a disproportionately large number of ... expensive to produce, and fewer lenses in the ...
The LM-990A is the most completely automatic lensemeter ever created. It even measured monocular and binocular PD automatically....
... has made the LM-770 the easiest ... Technicians can be trained to operate ... instruction. The instrument tells the user ... A flashing indicator alerts the user ...
... designed to perform precise and accurate ... one-third the space of traditional examinations. ... refractors, automatic or digital lensmeters and ... EPIC enables the operator to call ...
Medicine Products: